Latest Conference Articles

November 9th 2022, 6:00pm

PER® Chemotherapy Foundation Symposium (CFS)

Daniel P. Petrylak, MD, highlights the use of checkpoint inhibitors, antibody-drug conjugates, and FGFR inhibitors in urothelial cancer and the current sequencing hurdles in the paradigm.

November 9th 2022, 3:04pm

PER® Chemotherapy Foundation Symposium (CFS)

The Chemotherapy Foundation Symposium® returns to New York City for its 40th annual meeting with a 3-day program that will deliver the latest updates across the gamut of oncology care.

November 6th 2022, 11:00am

International Kidney Cancer Symposium

Kiran Virdee, RN, BSN, CCRN-K, outlines the best practices for the management of adverse effects during the treatment of kidney cancer.

November 5th 2022, 12:30pm

International Kidney Cancer Symposium

Rana M. McKay, MD, and Yousef Zakharia, MD, debate the pros and cons of doublet vs triplet combination therapies in the frontline setting for patients with renal cell carcinoma.

November 5th 2022, 12:00pm

International Kidney Cancer Symposium

Tivozanib continued to display a progression­-free survival benefit and rates vs sorafenib in patients with relapsed/refractory renal cell carcinoma who received 2 or 3 prior systemic regimens.

November 4th 2022, 8:45pm

International Kidney Cancer Symposium

Rana R. McKay, MD, discusses the rationale for combining tivozanib with nivolumab in heavily pretreated patients with renal cell carcinoma.

November 4th 2022, 8:30pm

International Kidney Cancer Symposium

The combination of nivolumab and ipilimumab led to significant improvements in survival vs sunitinib in patients with intermediate- and poor-risk renal cell carcinoma with sarcomatoid features.

November 4th 2022, 7:46pm

International Kidney Cancer Symposium

Lenvatinib plus pembrolizumab reduced the need for second-line therapy by 42.8% compared with sunitinib in patients with advanced renal cell carcinoma.

November 4th 2022, 7:25pm

International Kidney Cancer Symposium

Bradley McGregor, MD, discusses the rationale behind combining belzutifan with lenvatinib in pretreated patients with advanced renal cell carcinoma with clear cell components.

November 4th 2022, 7:19pm

Eric Jonasch, MD, discusses the exploration of cabozantinib in the neoadjuvant setting in renal cell carcinoma.

November 4th 2022, 7:00pm

Andrew W. Hahn, MD, discusses the investigation of lenvatinib plus everolimus vs cabozantinib in metastatic renal cell carcinoma following progression on an immune checkpoint inhibitor.

November 4th 2022, 6:20pm

International Kidney Cancer Symposium

Patients with treatment-naïve advanced renal cell carcinoma who received nivolumab plus cabozantinib achieved deeper objective responses leading to improved progression-free survival and overall survival rates vs those who received sunitinib, according to exploratory data from the CheckMate 9ER trial.

November 4th 2022, 5:20pm

International Kidney Cancer Symposium

The combination of lenvatinib plus everolimus is under evaluation vs cabozantinib in the phase 2 LenCabo trial for patients with metastatic renal cell carcinoma who have progressed on prior treatment with a PD-1/PD-L1 immune checkpoint inhibitor.

November 4th 2022, 3:00pm

International Kidney Cancer Symposium

Bradley McGregor, MD, discusses the factors that affect frontline treatment decisions for patients with advanced RCC, the importance of longer-term follow-up of phase 3 trials in kidney cancer, and the benefits of dual immunotherapy and immunotherapy/TKI treatment combinations.

November 4th 2022, 1:06pm

International Kidney Cancer Symposium

Eric Jonasch, MD, discusses key clinical trials that are paving the way for improved treatment sequencing in renal cell carcinoma and the prospective benefits of neoadjuvant cabozantinib in nonmetastatic clear cell renal cell carcinoma.

October 29th 2022, 10:00am

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Benjamin Adam Weinberg, MD, discussed the expanding role of circulating tumor DNA in CRC and the various testing methods, the utilization of liquid biopsies, and the need for up-front genetic testing to identify molecular alterations.

October 14th 2022, 5:05pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

As research and treatment options for patients with mantle cell lymphoma continue to expand, the development of risk-adapted therapies for the 3 primary subtypes—blastoid, smoldering, and classic broad-spectrum—represents a crucial next step in the field.

October 13th 2022, 6:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Treatment with ibrutinib for at least 5 years showed favorable complete response rates and tolerability in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were randomized to receive the BTK inhibitor in the phase 3 RESONATE-2 trial.

October 13th 2022, 1:43pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Fixed-duration treatment with ibrutinib and venetoclax led to deeper and prolonged undetectable minimal residual disease responses vs chlorambucil and obinutuzumab in the frontline treatment of elderly or unfit patients with chronic lymphocytic leukemia, translating to fewer relapses in the first year following treatment cessation.

October 9th 2022, 10:00am

Society of Hematologic Oncology Annual Meeting (SOHO)

Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial.